Memorandum of Understanding (MOU) signed for strategic collaboration in viral vector manufacturing
On September 10th, 인터넷 바카라 therapy expert Curocell, led by CEO Gunsoo Kim, announced the formalization of a strategic partnership through the signing of a Memorandum of Understanding (MOU) with Genscript Probio, headed by CEO Patrick Liu. The collaboration aims to advance the development of next-generation 인터넷 바카라 therapies, with a specific focus on the manufacturing of viral vectors.
Under this agreement, both entities will engage in a comprehensive strategic collaboration encompassing the research, development, and clinical trials of 인터넷 바카라 therapies. Viral vectors, integral to 인터넷 바카라 therapies, serve as virus-based delivery systems for transferring genetic material into cells. The surge in demand for viral vectors aligns with the expanding gene therapy and 인터넷 바카라 therapy markets.
Patrick Liu, CEO of Genscript Probio, expressed enthusiasm about the MOU, emphasizing the pleasure of partnering with Curocell, a leading 인터넷 바카라 therapy company in Korea, for the manufacturing and supply of viral vectors. He stated, "I am delighted to establish a close collaborative relationship with Curocell for the production and supply of viral vectors, contributing not only to the Korean market but also to the global advancement of 인터넷 바카라 therapies. Through this partnership, we will continue working closely with Curocell to facilitate the expansion of 인터넷 바카라 therapies both domestically and internationally."
Gunsoo Kim, CEO of Curocell, highlighted the collaboration's significance, stating, "Through this agreement, we have forged a robust collaborative foundation spanning the developmental stages to the commercialization of 인터넷 바카라 therapies." He added, "Curocell aims to emerge as a global leader in anti-cancer immunotherapy through our partnership with Genscript Probio, a globally recognized company in the gene therapy field."